A colleague recently told me that he is actively treating more than 250 patients at three separate locations. "Do you think I need a computer?" he asked. That is a question many psychiatrists are asking as they see more patients and do an increasing amount of paperwork to maintain the same income they earned with far fewer patients just five years ago.
In recent years, psychiatry and psychoanalysis have been drifting apart. As has been stated, psychiatry is losing its mind as it concentrates on chemistry and biology. This is a pity, because it is always good to have a mind.
Venlafaxine (Effexor) is a novel antidepressant recently released to the American market. Its entry into the antidepressant market has been much heralded. The lay press has described the drug as "Prozac with a punch," and many patients were asking for it long before it was available. As the hoopla settles down, we are learning that venlafaxine is a potentially important drug with both advantages and disadvantages over other available antidepressants, including the selective serotonin reuptake inhibitors (SSRIs).
